Review article: explaining risks of inflammatory bowel disease therapy to patients

被引:92
作者
Siegel, C. A. [1 ]
机构
[1] Dartmouth Hitchcock Med Ctr, Ctr Inflammatory Bowel Dis, Sect Gastroenterol & Hepatol, Lebanon, NH 03756 USA
关键词
CROHNS-DISEASE; CORTICOSTEROID-THERAPY; RHEUMATOID-ARTHRITIS; DECISION-MAKING; METHOTREXATE; INFLIXIMAB; BENEFITS; COMMUNICATION; AZATHIOPRINE; LYMPHOMA;
D O I
10.1111/j.1365-2036.2010.04489.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
P>Background Medical treatment for inflammatory bowel disease (IBD) has advanced significantly over the past decade, but it is important to communicate effectively the balance of benefits and risks of therapy to patients to facilitate informed medical decisions. Aim To review the available data describing the risk of side effects of IBD medications and to describe effective methods for communicating risk. Methods To identify relevant articles for this review, a PubMed search was conducted using relevant key words and phrases. In addition, reference lists from identified manuscripts were searched and recent abstracts from National meetings were reviewed. Results The steroid-sparing medications used for the treatment of IBD all carry risks of both common and rare adverse events. Trade-offs need to be made between the risks of these medications vs. the risks of poorly treated disease and corticosteroids. There has been significant research on how best to present risk data to patients, which is summarized in this review. Conclusions To ensure that our patients understand their choices and feel comfortable with their treatment, we need to communicate risk data to patients clearly. Patients comprehend absolute numbers better than relative risk, and when available, pictorial representations of data are preferred over solely presenting numerical outcomes.
引用
收藏
页码:23 / 32
页数:10
相关论文
共 51 条
[31]   Immunosuppressant medications and mortality in inflammatory bowel disease [J].
Lewis, James D. ;
Gelfand, Joel M. ;
Troxel, Andrea B. ;
Forde, Kimberly A. ;
Newcomb, Craig ;
Kim, Hopiy ;
Margolis, David J. ;
Strom, Brian L. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (06) :1428-1435
[32]   Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry [J].
Lichtenstein, GR ;
Feagan, BG ;
Cohen, RD ;
Salzberg, BA ;
Diamond, RH ;
Chen, DM ;
Pritchard, ML ;
Sandborn, WJ .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (05) :621-630
[33]   Numeric, verbal, and visual formats of conveying health risk: Suggested best practices and future recommendations [J].
Lipkus, Isaac M. .
MEDICAL DECISION MAKING, 2007, 27 (05) :696-713
[34]   Methotrexate hepatotoxicity in psoriatics: Report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up [J].
Malatjalian, DA ;
Williams, CN ;
Colwell, SJ ;
Eastwood, BJ .
CANADIAN JOURNAL OF GASTROENTEROLOGY, 1996, 10 (06) :369-375
[35]   Numeracy skill and the communication, comprehension, and use of risk-benefit information [J].
Peters, Ellen ;
Hibbard, Judith ;
Slovic, Paul ;
Dieckmann, Nathan .
HEALTH AFFAIRS, 2007, 26 (03) :741-748
[36]  
Present DH, 2000, INFLAMM BOWEL DIS, V6, P48, DOI 10.1097/00054725-200002000-00009
[37]   A Theory of Medical Decision Making and Health: Fuzzy Trace Theory [J].
Reyna, Valerie F. .
MEDICAL DECISION MAKING, 2008, 28 (06) :850-865
[38]   A COMPARISON OF BUDESONIDE WITH PREDNISOLONE FOR ACTIVE CROHNS-DISEASE [J].
RUTGEERTS, P ;
LOFBERG, R ;
MALCHOW, H ;
LAMERS, C ;
OLAISON, G ;
JEWELL, D ;
DANIELSSON, A ;
GOEBELL, H ;
THOMSEN, OO ;
LORENZMEYER, H ;
HODGSON, H ;
PERSSON, T ;
SEIDEGARD, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (13) :842-845
[39]   Review article: the limitations of corticosteroid therapy in Crohn's disease [J].
Rutgeerts, PJ .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (10) :1515-1525
[40]   The role of numeracy in understanding the benefit of screening mammography [J].
Schwartz, LM ;
Woloshin, S ;
Black, WC ;
Welch, HG .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (11) :966-972